CSIMarket
 


Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 

Cumulative Odonate Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

ODT's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ODT Quick Ratio for Trailing Twelve Months Period

(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Current Liabilities Growth 6.17 % 16.02 % 32.15 % 9.26 % 15.22 %
Y / Y Cash & cash equivalent Growth -49.52 % -12.19 % -13.03 % -12.85 % -7.83 %
Quick Ratio for Trailing Twelve Months Period 4.13 4.98 5.29 5.88 6.23
Total Ranking # 855 # 715 # 643 # 472 # 421
Seq. Current Liabilities Growth 2.18 % -10.41 % 22.24 % -5.12 % 11.66 %
Seq. Cash & cash equivalent Growth -13.71 % -17.3 % -15.33 % -16.46 % 50.11 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2021
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $30 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 4.13 below Odonate Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 323 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Odonate Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ODT
Quick Ratio ODT in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 324
Sector # 553
S&P 500 # 1001


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
16.95 6.78 0.43
(Mar 31 2018)   (Dec 31 2017)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Virpax Pharmaceuticals Inc   11.24 
Morphic Holding inc   11.21 
Immunic Inc   11.04 
Zai Lab Limited  10.90 
Syndax Pharmaceuticals Inc   10.87 
Effector Therapeutics Inc   10.82 
Larimar Therapeutics Inc   10.68 
Bolt Biotherapeutics Inc   10.66 
Protokinetix Incorporated  10.64 
Zentalis Pharmaceuticals Inc   10.55 
Gracell Biotechnologies Inc   10.51 
Cryoport inc   10.49 
Renovaro Inc   10.47 
Agios Pharmaceuticals Inc   10.27 
Homology Medicines Inc  10.20 
Schrodinger Inc   10.17 
Cytokinetics Incorporated  10.08 
Sio Gene Therapies Inc   9.89 
Mirati Therapeutics Inc   9.79 
Trevena inc   9.77 
Scpharmaceuticals Inc   9.68 
Cara Therapeutics inc   9.64 
Frequency Therapeutics Inc   9.63 
Royalty Pharma Plc  9.37 
Ovid Therapeutics Inc   9.34 
Iveric Bio Inc   9.32 
Chinook Therapeutics Inc   9.31 
Marinus Pharmaceuticals Inc   9.27 
Kiniksa Pharmaceuticals ltd   9.25 
Landos Biopharma Inc   9.22 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com